Date |
Product |
Disease |
Phase |
Company |
Therapeutic area |
2017-09-21
|
Invir.IO™ |
|
|
Transgene (France) |
Cancer - Oncology |
2017-09-21
|
Tremfya® (guselkumab) |
psoriatic arthritis |
3 |
Janssen Research & Development, a J&J company (USA - NJ) |
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases |
2017-09-21
|
Diamyd® |
type 1 diabetes |
2 |
Diamyd Medical (Sweden) |
Autoimmune diseases - Metabolic diseases |
2017-09-21
|
NeuroSTAT® (cyclosporine) |
traumatic brain injury |
2b |
Neurovive Pharmaceutical (Sweden) |
Traumatology - CNS diseases |
2017-09-20
|
PXL770 |
type 2 diabetes |
1b |
Poxel (France) |
Metabolic diseases |
2017-09-20
|
Intuniv® (guanfacine hydrochloride prolonged release) |
attention deficit hyperactivity disorder (ADHD) |
3 |
Shire (UK - USA) Shionogi (Japan) |
Mental diseases - CNS diseases |
2017-09-20
|
Trelegy Ellipta® (combination of fluticasone furoate, umeclidinium and vilanterol) |
chronic obstructive pulmonary disease (COPD) |
3 |
GSK (UK) Theravance, now Innoviva (USA - CA) |
Respiratory diseases |
2017-09-19
|
TG4001 in combination with avelumab |
human papilloma virus- (HPV-) positive head and neck squamous cell carcinoma (HNSCC), after failure of standard therapy |
1b-2 |
Transgene (France) |
Cancer - Oncology |
2017-09-19
|
NanoFlu™ vaccine |
influenza |
1-2 |
Novavax (USA - MD) |
Infectious diseases |
2017-09-18
|
tesofensine |
obesity |
3 |
Saniona (Denmark) Medix (Mexico) |
Metabolic diseases |
2017-09-18
|
PQ Grass |
grass pollen-induced allergic rhinitis |
2 |
Allergy Therapeutics (UK) |
Allergic diseases |
2017-09-18
|
AUTO2 |
multiple myeloma |
1-2 |
Autolus (UK) |
Cancer - Oncology |
2017-09-18
|
AUTO3 |
acute lymphoblastic leukaemia |
1-2 |
Autolus (UK) |
Cancer - Oncology |
2017-09-18
|
AUTO3 |
diffuse large B-cell lymphoma (DLBCL) |
1-2 |
Autolus (UK) |
Cancer - Oncology |
2017-09-16
|
dupilumab |
moderate-to-severe atopic dermatitis |
3 |
Sanofi (France) Regeneron Pharmaceuticals (USA - NY) |
Autoimmune diseases - Dermatological diseases |
2017-09-16
|
|
|
|
|
|
2017-09-16
|
Tremfya™ (guselkumab - CNTO 1959) |
psoriasis |
3 |
Janssen Research & Development, a J&J company (USA - NJ) |
Autoimmune diseases - Dermatological diseases |
2017-09-15
|
Repatha™ (evolocumab) |
reduction of recurrent cardiovascular events |
3 |
Amgen (USA - CA) |
Cardiovascular diseases - Metabolic diseases |
2017-09-14
|
imeglimin |
type 2 diabetes |
2b |
Poxel (France) |
Metabolic diseases |
2017-09-14
|
baricitinib (LY3009104) |
moderate-to-severe atopic dermatitis |
2 |
Eli Lilly (USA - IN) Incyte Corporation (USA - DE) |
Dermatological diseases - Inflammatory diseases |